Systemic Therapy in Combination with Stereotactic Radiotherapy in Patients with Metastatic Colorectal Cancer Up to 10 Metastatic Sites
Key facts
- Who runs it
- UMC Utrecht
- Where
- Netherlands4 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Suspended
- Phase
- Phase 2
- People taking part
- 93 people, planned
- Started
- 1 Dec 2025
- Expected to end
- 1 Jun 2034
- Type of study
- Interventional, 2 groupsOne group gets an existing treatment, for comparison.
- Treatments tested
- Stereotactic body radiation therapy (SBRT)
- Maintenance therapy (CAP-B or 5-FU/LV plus bevacizumab.)
- Record updated
- 28 March 2025
- Why it stopped
- Pilot study findings pointed to a overhaul in study design
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 21 criteriaShow less
Who can take part
- Registered in the prospective Dutch colorectal cancer cohort (PLCRC)
- Intention at start of palliative systemic therapy to receive six maximum tolerated dose (MTD) cycles of CAPOX-B or eight MTD cycles of FOLFOX-B or FOLFOXIRI-B
- Ten or less metastases as determined by the university medical center Utrecht (UMCU) central review
- Stable disease or partial response after initial chemotherapy according to RECIST 1.1 criteria
- Expected adequacy of follow-up
- World Health organization (WHO) performance status 0-1
- Life expectancy >12 weeks
- Adequate organ functions at start of initial therapy, as determined by normal bone marrow function (Hb≥6.0 mmol/L, absolute neutrophil count ≥1.5 x 10\^9/L, platelets ≥100 x 10\^9/L), renal function (serum creatinine ≤ 1.5x upper limit of normal (ULN) and creatinine clearance, Cockcroft formula, ≥30 ml/min) and liver function (serum bilirubin ≤ 2 x ULN, serum transaminases ≤ 3 x ULN without presence of liver metastases or ≤ 5x ULN with presence of liver metastases)
- Written informed consent (SIRIUS)
Who cannot take part
- Possible treatment with curative intent according to local tumor board
- Substantial overlap with a previously treated radiation volume. Previous radiotherapy is allowed as long as the composite plan meets dose constraints herein
- Not amenable for radiotherapy (e.g. peritonitis carcinomatosa)
- Previous systemic treatment for metastatic disease; prior adjuvant treatment for stage II/III colorectal cancer when given >6 months before the start of initial systemic treatment is allowed
- Any concomitant experimental treatment
- Serious comorbidity or any other condition preventing the safe administration of treatment (including both systemic treatment and radiation)
- Other malignancy interfering with prognosis
- Less than three cycles of CAPOX-B or four cycles of FOLFOX-B or FOLFOXIRI-B (dose reductions allowed)
- More than six cycles of CAPOX-B or eight cycles of FOLFOX-B of FOLFOXIRI-B
- Pregnant or lactating women
- Contra-indication MR-LINAC (pacemaker or implantable cardioverter-defibrillator)
- Microsatellite instability or deficient mismatch repair tumor
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
A small number of colorectal cancer patients with limited oligometastases may be candidates for local treatment of metastases (e.g., resection, ablation). However, it is unclear if patients with more extensive metastatic disease benefit from local therapies to control visible metastasis.
Read full original descriptionShow less
The purpose of this study is to assess the impact of stereotactic body radiation therapy (SBRT) in combination with systemic therapy compared to systemic therapy alone on safety and efficacy in patients with metastatic colorectal cancer (mCRC) and ≤10 metastases.
The 2 groups in the trial
- Systemic maintenance therapyExisting treatment, for comparison
Treatment: Maintenance therapy (CAP-B or 5-FU/LV plus bevacizumab.)
- Systemic maintenance therapy in combination with stereotactic body radiation therapy (SBRT)Treatment being tested
Treatment: Stereotactic body radiation therapy (SBRT) and Maintenance therapy (CAP-B or 5-FU/LV plus bevacizumab.)
Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- A Multicenter Phase II Randomized Trial to Evaluate Systemic Therapy Versus Systemic Therapy in Combination with Stereotactic Radiotherapy in Patients with Metastatic Colorectal Cancer
- Record updated
- 28 March 2025